Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells

International Journal of Molecular Medicine

Volumn 30, Issue 2, 2012, Pages 443-450

  Lee, Su Jin ^a   Park, Ho Jin ^a   Kim, Young Hwa ^a   Kim, Bo Young ^a   Jin, Hyun Seok ^a   Kim, Hyon J ^a   Han, Jae Ho ^a   Yim, Hyunee ^a   Jeong, Seon Yong ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

ABT 737; Apoptosis; Bcl xL; Doxorubicin; Malignant peripheral nerve sheath tumor; Neurofibromatosis type 1

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; DOXORUBICIN; NEUROFIBROMIN; PROTEIN BAD; PROTEIN BCL XL;

ADULT; APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, NEUROFIBROMATOSIS 1; HUMANS; MALE; NEUROFIBROMATOSIS 1; NITROPHENOLS; PIPERAZINES; SULFONAMIDES; YOUNG ADULT;

EID: 84863551552     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1013     Document Type: Article

References (43)

1. McClatchey AI: Neurofibromatosis. Annu Rev Pathol 2: 191-216, 2007.
2. Jett K and Friedman JM: Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12: 1-11, 2010.
3. Savar A and Cestari DM: Neurofibromatosis type I: genetics and clinical manifestations. Semin Ophthalmol 23: 45-51, 2008.
4. Dasgupta B and Gutmann DH: Neurofibromatosis 1: closing the GAP between mice and men. Curr Opin Genet Dev 13: 20-27, 2003.
5. Grobmyer SR, Reith JD, Shahlaee A, Bush CH and Hochwald SN: Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 97: 340-349, 2008.
6. Katz D, Lazar A and Lev D: Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med 11: e30, 2009.
7. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E and Moran A: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39: 311-314, 2002.
8. Muir D, Neubauer D, Lim IT, Yachnis AT and Wallace MR: Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 158: 501-513, 2001.
9. Gupta A, Cohen BH, Ruggieri P, Packer RJ and Phillips PC: Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology 60: 130-132, 2003.
10. Citak EC, Oguz A, Karadeniz C, Okur A, Memis L and Boyunaga O: Management of plexiform neurofibroma with interferon alpha. Pediatr Hematol Oncol 25: 673-678, 2008.
11. Babovic-Vuksanovic D, Ballman K, Michels V, et al: Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 67: 1860-1862, 2006.
12. Widemann BC, Salzer WL, Arceci RJ, et al: Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 24: 507-516, 2006.
13. Kinebuchi Y, Noguchi W, Igawa Y and Nishizawa O: Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin Oncol 10: 353-356, 2005.
14. Landy H, Feun L, Markoe A, et al: Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report. J Neurosurg 103: 760-763, 2005.
15. Moretti VM, Crawford EA, Staddon AP, Lackman RD and Ogilvie CM: Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol 34: 417-421, 2011.
16. Kroep JR, Ouali M, Gelderblom H, et al: First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol 22: 207-214, 2011.
17. Ferrari A, Miceli R, Rey A, et al: Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer 47: 724-731, 2011.
18. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006.
19. Bhola P, Banerjee S, Mukherjee J, et al: Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer 126: 563-571, 2010.
20. Ambrosini G, Cheema HS, Seelman S, et al: Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 7: 890-896, 2008.
21. Holtkamp N, Malzer E, Zietsch J, et al: EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol 10: 946-957, 2008.
22. Wojtkowiak JW, Fouad F, LaLonde DT, et al: Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther 326: 1-11, 2008.
23. Jeong SY, Park SJ and Kim HJ: The spectrum of NF1 mutations in Korean patients with neurofibromatosis type 1. J Korean Med Sci 21: 107-112, 2006.
24. Jeong SY, Han JH, Park YY and Kim HJ: Identification of differentially expressed genes related to NF1-associated malignant transformation from a patient with neurofibromatosis type 1. Genes Genomics 30: 407-418, 2008.
25. Li Y, Rao PK, Wen R, et al: Notch and Schwann cell transformation. Oncogene 23: 1146-1152, 2004.
26. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS and Downward J: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356: 713-715, 1992.
27. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681, 2005.
28. Legius E, Marchuk DA, Collins FS and Glover TW: Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 3: 122-126, 1993.
29. Koga T, Iwasaki H, Ishiguro M, Matsuzaki A and Kikuchi M: Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis. J Pathol 197: 98-107, 2002.
30. Subramanian S, Thayanithy V, West RB, et al: Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 220: 58-70, 2010.
31. Harder A, Rosche M, Reuss DE, et al: Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. Eur J Cancer 40: 2820-2828, 2004.
32. Sevilla L, Zaldumbide A, Pognonec P and Boulukos KE: Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families. Histol Histopathol 16: 595-601, 2001.
33. Kirkin V, Joos S and Zornig M: The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644: 229-249, 2004.
34. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC and Fornace AJ Jr: An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 60: 6101-6110, 2000.
35. Littlejohn JE, Cao X, Miller SD, et al: Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer 123: 202-208, 2008.
36. Brotin E, Meryet-Figuiere M, Simonin K, et al: Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer 126: 885-895, 2010.
37. Azmi AS and Mohammad RM: Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 218: 13-21, 2009.
38. Richardson A and Kaye SB: Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol 1: 244-254, 2008.
39. Reynoso D, Nolden LK, Yang D, et al: Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol Oncol 5: 93-104, 2011.
40. van Delft MF, Wei AH, Mason KD, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399, 2006.
41. Touzeau C, Dousset C, Bodet L, et al: ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res 17: 5973-5981, 2011.
42. Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR and Cutts SM: ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol 79: 339-349, 2010.
43. Lim D and Muir J: Imatinib for chronic myeloid leukaemia: a NICE mess. Lancet 358: 1903, 2001.